Pediatric Exclusivity Will Not Irreparably Harm Generic Firms, Court Says

Exclusivity extensions under FDAMA's pediatric provisions will not cause "irreparable harm" to generic drug manufacturers, D.C. Federal Court Judge James Robertson maintained in an April 20 denial of a generics industry motion for preliminary injunction.